- Canopy’s joint ventures are providing cannabis-based medicinal products in the UK and Poland
- Company is expanding medicinal cannabis operations internationally
Canopy Growth (CGC) has established joint ventures, Spectrum Cannabis, to build a pan-European cannabis production and distribution network serving the needs of patients and physicians across the continent.
Under the British government’s new classification, which took effect November 1, specialist doctors in the UK can prescribe cannabis-based medicines to patients managing a wide range of symptoms – from chronic pain, chemotherapy-induced nausea and vomiting, to muscle spasticity for those with multiple sclerosis.
Spectrum Biomedical UK, a joint venture subsidiary of Canopy, now has the opportunity to introduce medicinal cannabis products to UK patient groups and doctors.
Similarly, Canopy’s JV entity has received regulatory approval to have its products assessed and approved for sale in Poland.
Article by: Mick Ross
Mick is currently a full-time investor and formerly a buy-side analyst (2yrs) covering healthcare companies. Before that, he was a salesperson at a bulge-bracket firm, based in Dallas, Texas. Mick blogs to clarify and synthesize his investment thought process and to elicit feedback; additionally he likes to connect with other investors and swap ideas.